AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8873689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (single intravenous bolus dose, doses ranged from 0.005 to 0.100 mg/kg)
Number of subjects: 53
Study 8873689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (single intravenous bolus dose)
Number of subjects: 53
Study 1300059 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 12.5 mg
Number of subjects: 26
Study 1300059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6208312 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual presentations
Number of subjects: 0
Study 6208312 — intervention group
Group type: COMPARATOR
Intervention: Pamphlets
Number of subjects: 0
Study 6208312 — intervention group
Group type: COMPARATOR
Intervention: One-to-one dialogue
Number of subjects: 0
Study 31539373 — intervention group
Group type: COMPARATOR
Intervention: Control vignette (typical woman)
Number of subjects: 1355
Study 31539373 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette portraying untreated mental illness
Number of subjects: 1355
Study 31539373 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette portraying effectively treated mental illness or treatment followed by subsequent relapse
Number of subjects: 1355
Study 29653069 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises (30 min/session, 7 times/week for 12 weeks)
Number of subjects: 35
Study 29653069 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 26716683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad containing a goal expectation violation manipulation
Number of subjects: 0
Study 26716683 — intervention group
Group type: COMPARATOR
Intervention: Control ad
Number of subjects: 0
Study 24447043 — intervention group
Group type: COMPARATOR
Intervention: Brown Rice (BR)
Number of subjects: 15
Study 24447043 — intervention group
Group type: COMPARATOR
Intervention: Brown Rice with Legumes (BRL)
Number of subjects: 15
Study 24447043 — intervention group
Group type: EXPERIMENTAL
Intervention: White Rice (WR)
Number of subjects: 15
Study 22415477 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks) with chemotherapy
Number of subjects: 159
Study 22415477 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (placebo)
Number of subjects: 159
Study 22415477 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy
Number of subjects: 159
Study 20854598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandal‐type specialty school furniture
Number of subjects: 30
Study 20854598 — intervention group
Group type: COMPARATOR
Intervention: Standard school furniture
Number of subjects: 30
Study 17926436 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral graded activity (BGA)
Number of subjects: 200
Study 17926436 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 200
Study 16303936 — intervention group
Group type: EXPERIMENTAL
Intervention: linoleic acid (LA; 112 mg) and gamma‐linolenic acid (GLA; 15 mg) administered twice daily for 1 month
Number of subjects: 40
Study 16303936 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily for 1 month
Number of subjects: 40
Study 11575865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg four times daily (240 mg/d)
Number of subjects: 85
Study 11575865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg four times daily (120 mg/d)
Number of subjects: 85
Study 11575865 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 85
Study 11575865 — intervention group
Group type: COMPARATOR
Intervention: Stroke patients
Number of subjects: 85
Study 11575865 — intervention group
Group type: COMPARATOR
Intervention: Stroke patients and control subjects pooled
Number of subjects: 85
Study 9284774 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 343
Study 9284774 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 343
Study 8349366 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin exercise treatment (5000 IU intravenous dose, treadmill exercise 20 times for 2-3 weeks)
Number of subjects: 6
Study 8349366 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients (control group)
Number of subjects: 6
Study 3329125 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M) 2550 mg/day
Number of subjects: 10
Study 3329125 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 3329125 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 10
Study 2688804 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (20 Gy in four fractions)
Number of subjects: 186
Study 2688804 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 186
Study 2688804 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 186
Study 30293208 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (15 g prebiotics and 5 g probiotics containing Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum) for 12 weeks
Number of subjects: 75
Study 30293208 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (5 g probiotics and 15 g maltodextrin) for 12 weeks
Number of subjects: 75
Study 30293208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 g maltodextrin) for 12 weeks
Number of subjects: 75
Study 27487193 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate 18 mg (with potential increases up to 72 mg/d)
Number of subjects: 341
Study 27487193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 27487193 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 341
Study 25617762 — intervention group
Group type: EXPERIMENTAL
Intervention: zopiclone 5 mg
Number of subjects: 16
Study 25617762 — intervention group
Group type: EXPERIMENTAL
Intervention: zopiclone 10 mg
Number of subjects: 16
Study 25617762 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol 50 g
Number of subjects: 16
Study 25617762 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 23896972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-marrow derived cell therapy (BMC) with a cell number above the median (324 × 10^6)
Number of subjects: 42
Study 23896972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-marrow derived cell therapy (BMC) with a cell number below the median
Number of subjects: 42
Study 23896972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-marrow derived cell therapy (BMC) without microvascular obstruction (MO)
Number of subjects: 42
Study 23896972 — intervention group
Group type: COMPARATOR
Intervention: Bone-marrow derived cell therapy (BMC)
Number of subjects: 42
Study 21521847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU daily for 96 weeks)
Number of subjects: 173
Study 21521847 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg daily for 96 weeks)
Number of subjects: 173
Study 21521847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 96 weeks)
Number of subjects: 173
Study 21521847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 173
Study 21521847 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 173
Study 21521847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 19892091 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate commencement of exercises within 2 hours after surgery
Number of subjects: 30
Study 19892091 — intervention group
Group type: COMPARATOR
Intervention: Control group commencing exercises on the first postoperative day
Number of subjects: 30
Study 19892091 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate commencement of exercises
Number of subjects: 30
Study 16977654 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 U once weekly for < or = 16 weeks)
Number of subjects: 269
Study 16977654 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (delayed treatment until hemoglobin < 9 g/dL)
Number of subjects: 269
Study 15807201 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast
Number of subjects: 20
Study 15807201 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat breakfast
Number of subjects: 20
Study 10917932 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyanidin-rich chocolate (5.3 mg total procyanidin/g, 1.3 mg/g (‐)‐epicatechin)
Number of subjects: 0
Study 10917932 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyanidin-rich chocolate
Number of subjects: 0
Study 9062608 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.5% end-tidal concentration for 10 min (Group Iso-10)
Number of subjects: 45
Study 9062608 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.5% end-tidal concentration for 30 min (Group Iso-30)
Number of subjects: 45
Study 9062608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen for 10 min (Group N2O)
Number of subjects: 45
Study 8399641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium concentration dialysate (1.00 mM)
Number of subjects: 18
Study 8399641 — intervention group
Group type: COMPARATOR
Intervention: Standard calcium concentration dialysate (1.75 mM)
Number of subjects: 18
Study 3743529 — intervention group
Group type: EXPERIMENTAL
Intervention: Running program (3 sessions of 30 minutes per week for 12 weeks)
Number of subjects: 154
Study 3743529 — intervention group
Group type: EXPERIMENTAL
Intervention: Running program (for boys)
Number of subjects: 154
Study 3743529 — intervention group
Group type: EXPERIMENTAL
Intervention: Running program (for girls)
Number of subjects: 154
Study 3743529 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education program
Number of subjects: 154
Study 28430945 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention
Number of subjects: 746
Study 28430945 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 746
Study 28404091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (25 mg)
Number of subjects: 873
Study 28404091 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (300 mg)
Number of subjects: 873
Study 24385121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulonic acid (ALA) photodynamic therapy (PDT), two treatments, 2 weeks apart
Number of subjects: 0
Study 24385121 — intervention group
Group type: COMPARATOR
Intervention: Control group observed without treatment
Number of subjects: 0
Study 22910239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice with high concentrations of proanthocyanidin
Number of subjects: 40
Study 22910239 — intervention group
Group type: COMPARATOR
Intervention: Cranberry juice with no proanthocyanidin (placebo)
Number of subjects: 40
Study 20633186 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsies from macroscopic lesions
Number of subjects: 112
Study 20633186 — intervention group
Group type: COMPARATOR
Intervention: Non-targeted biopsies from the lesser curvature
Number of subjects: 112
Study 20633186 — intervention group
Group type: COMPARATOR
Intervention: Non-targeted biopsies from the antrum, angulus, and lesser curvature of the corpus
Number of subjects: 112
Study 18950301 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended sensor (BS)
Number of subjects: 547
Study 18950301 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer (XL)
Number of subjects: 547
Study 18950301 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BS and XL)
Number of subjects: 547
Study 16012762 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 62
Study 16012762 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 12873814 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone and furosemide (Group 1: 50 patients)
Number of subjects: 100
Study 12873814 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone alone (Group 2: 50 patients)
Number of subjects: 100
Study 10673292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten free diet including oats
Number of subjects: 92
Study 10673292 — intervention group
Group type: COMPARATOR
Intervention: Conventional gluten free diet
Number of subjects: 92
Study 9397291 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist treatment
Number of subjects: 0
Study 9397291 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study 8394193 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine-ER (5 to 20 mg once daily)
Number of subjects: 20
Study 3720571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g/day)
Number of subjects: 3806
Study 3720571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3806
Study 31882288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton‐tipped applicator test with 3 strokes at differing frequencies (10, 30, or 100 seconds)
Number of subjects: 36
Study 30767613 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBBT)
Number of subjects: 34
Study 30767613 — intervention group
Group type: COMPARATOR
Intervention: Weight shifting and gait training (WS&GT)
Number of subjects: 34
Study 28223274 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 98
Study 28223274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 26604731 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine (ER) 900 mg daily
Number of subjects: 40
Study 26604731 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 23406466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Health Communication Application (IHCA)
Number of subjects: 414
Study 23406466 — intervention group
Group type: COMPARATOR
Intervention: Standard website (control)
Number of subjects: 414
Study 23406466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored IHCA
Number of subjects: 414
Study 21870121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g ALC twice a day for 90 days
Number of subjects: 61
Study 21870121 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 61
Study 18644845 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 52
Study 18644845 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tubes
Number of subjects: 52
Study 16841184 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 23
Study 16841184 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 23
Study 12897593 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10971236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine foam enema (2 g per day)
Number of subjects: 111
Study 10971236 — intervention group
Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 111
Study 8649559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 1799929 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (various doses)
Number of subjects: 56
Study 1799929 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and hydrochlorothiazide combination
Number of subjects: 56
Study 1799929 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (new galenic form)
Number of subjects: 56
Study 6381336 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorimipramine (50 mg/day) + L-5-HTP (300 mg/day)
Number of subjects: 26
Study 6381336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6381336 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorimipramine + L-5-HTP
Number of subjects: 26
Study 30587415 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation (CPVI) + ablation of electrogram dispersion areas (group A)
Number of subjects: 142
Study 30587415 — intervention group
Group type: COMPARATOR
Intervention: Stepwise ablation strategy (group B)
Number of subjects: 142
Study 30292278 — intervention group
Group type: EXPERIMENTAL
Intervention: Single extracorporeal shock-wave lithotripsy (ESWL)
Number of subjects: 100
Study 30292278 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography texture analysis (CTTA) metrics
Number of subjects: 100
Study 25650318 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1g ketoprofen
Number of subjects: 169
Study 25650318 — intervention group
Group type: COMPARATOR
Intervention: 2.5g metamizole
Number of subjects: 169
Study 24850877 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 9
Study 21452042 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-3 mRNA expression in metastatic HCC patients
Number of subjects: 160
Study 21452042 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-4 mRNA expression in metastatic HCC patients
Number of subjects: 160
Study 21452042 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-3 mRNA expression in localized HCC patients
Number of subjects: 160
Study 21452042 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-4 mRNA expression in localized HCC patients
Number of subjects: 160
Study 21452042 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one type of mRNA in metastatic HCC patients
Number of subjects: 160
Study 21452042 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one type of mRNA in localized HCC patients
Number of subjects: 160
Study 21452042 — intervention group
Group type: COMPARATOR
Intervention: MAGE-4 mRNA expression in controls and cirrhotic patients
Number of subjects: 160
Study 19682769 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bexarotene 1% gel applied twice daily for 6 months
Number of subjects: 42
Study 17577801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (BUP) with standard cognitive-behavioral smoking cessation treatment (ST)
Number of subjects: 524
Study 17577801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBTD) with BUP
Number of subjects: 524
Study 17577801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBTD) with placebo (PLAC)
Number of subjects: 524
Study 17577801 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) plus placebo (PLAC)
Number of subjects: 524
Study 15223711 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1572
Study 15223711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1572
Study 15223711 — intervention group
Group type: COMPARATOR
Intervention: Overall (PCI and Fibrinolysis)
Number of subjects: 1572
Study 12437794 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho‐educational group (PEG) intervention
Number of subjects: 45
Study 12437794 — intervention group
Group type: COMPARATOR
Intervention: Routine Primary Care (RPC)
Number of subjects: 45
Study 9650013 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg t.i.d. and sodium selenite (Se) 500 micrograms per day for 24 weeks (group A)
Number of subjects: 24
Study 9650013 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, untreated for first 12 weeks)
Number of subjects: 24
Study 8895036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (10 mmol/day)
Number of subjects: 14
Study 8895036 — intervention group
Group type: COMPARATOR
Intervention: High sodium intake (350 mmol/day)
Number of subjects: 14
Study 2181158 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 213
Study 6103443 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrochemical sensor for estimating arterial oxygen (PaO2) and carbon dioxide (PaCO2) tensions
Number of subjects: 0
Study 31248346 — intervention group
Group type: EXPERIMENTAL
Intervention: High suicide risk vignette
Number of subjects: 420
Study 31248346 — intervention group
Group type: EXPERIMENTAL
Intervention: Low suicide risk vignette
Number of subjects: 420
Study 31248346 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived behavioral control
Number of subjects: 420
Study 31248346 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective norms
Number of subjects: 420
Study 31248346 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes
Number of subjects: 420
Study 31248346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between risk severity and perceived behavioral control
Number of subjects: 420
Study 30617431 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review therapy combined with memory specificity training (LRT-MST)
Number of subjects: 20
Study 28065679 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF DPI 200/12 μg
Number of subjects: 49
Study 28065679 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF DPI 800/48 μg
Number of subjects: 49
Study 28065679 — intervention group
Group type: COMPARATOR
Intervention: BDP/FF pMDI 200/12 μg
Number of subjects: 49
Study 28065679 — intervention group
Group type: COMPARATOR
Intervention: BDP/FF pMDI 800/48 μg
Number of subjects: 49
Study 28065679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 26398281 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 35
Study 26398281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24798675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 21507074 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) at 36 kHz for 5 min, dosage from 1.57 to 3.50 W/cm(2)
Number of subjects: 34
Study 21507074 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US)
Number of subjects: 34
Study 21507074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20118830 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-session motivational interviewing plus skills-building intervention (integrated intervention; n = 48)
Number of subjects: 79